Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ
61.48
-0.06 (-0.10%)
Closed
Oct 7, 2026
Day's Range
60.7862.75
52 wk Range
34.6195.49
Financial Statements - ARWR - Arrowhead Pharmaceuticals, Inc.
Revenue
829.44M▲ 23258.2%
Net Income
30.11M▲ 104.9%Net Margin 3.6%
EBITDA
164.82M▲ 129.4%
Free Cash Flow
156.88M▲ 126.0%
Income Statement
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|---|
| Sales | 829.44M | 3.55M | 240.73M | 243.23M | 138.28M | 87.99M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 98.34M | -601.08M | -205M | -178.50M | -149.03M | -93.15M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 5.25M | -1.74M | 1.53M | 765K | 2.07M | -583K |
| Pre Tax Income | 51.53M | -612.46M | -206.49M | -172.70M | -140.84M | -84.55M |
| Income Tax | 21.41M | -2.76M | 2.78M | 3.78M | 2K | 2K |
| Net Income | 30.11M | -609.69M | -209.27M | -176.49M | -140.84M | -84.55M |
| EPS Basic | -0.01 | -5 | -1.91288 | -1.629945 | -1.36 | -0.84 |
| EPS Diluted | -0.01 | -5 | -1.92 | -1.67 | -1.36 | -0.84 |
| Basic Shares Outstanding | 133.75M | 119.78M | 107.31M | 105.96M | 103.74M | 100.72M |
| Diluted Shares Outstanding | 133.75M | 119.78M | 107.31M | 105.96M | 103.74M | 100.72M |
| Ebit | 140.89M | -580.10M | -188.16M | -172.70M | -140.84M | -93.15M |
| Ebitda | 164.82M | -561.51M | -175.67M | -162.28M | -132.57M | -87.21M |
| Net Income Continuous Operations | 30.11M | -609.69M | -209.27M | -176.49M | -140.84M | -84.55M |
| Minority Interests | -31.74M | 10.20M | 4M | 431K | 0 | 0 |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
